Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma. - Université de Lille Accéder directement au contenu
Article Dans Une Revue American Journal of Respiratory and Critical Care Medicine Année : 2017

Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.

Elizabeth A Kelly
  • Fonction : Auteur
Lin Ying Liu
  • Fonction : Auteur
Michael D Evans
  • Fonction : Auteur
Mats W Johansson
  • Fonction : Auteur
Sameer Mathur
  • Fonction : Auteur
Deane F Mosher
  • Fonction : Auteur
Loren C Denlinger
  • Fonction : Auteur
Nizar N Jarjour
  • Fonction : Auteur

Résumé

Mepolizumab, an IL-5-blocking antibody, reduces exacerbations in patients with severe eosinophilic asthma. Mepolizumab arrests eosinophil maturation; however, the functional phenotype of eosinophils that persist in the blood and airway after administration of IL-5 neutralizing antibodies has not been reported. To determine the effect of anti-IL-5 antibody on the numbers and phenotypes of allergen-induced circulating and airway eosinophils. Airway inflammation was elicited in participants with mild allergic asthma by segmental allergen challenge before and 1 month after a single intravenous 750-mg dose of mepolizumab. Eosinophils were examined in blood, bronchoalveolar lavage, and endobronchial biopsies 48 hours after challenge. Segmental challenge without mepolizumab induced a rise in circulating eosinophils, bronchoalveolar lavage eosinophilia, and eosinophil peroxidase deposition in bronchial mucosa. IL-5 neutralization before allergen challenge abolished the allergen-induced rise in circulating eosinophils and expression of IL-3 receptors, whereas airway eosinophilia and eosinophil peroxidase deposition were blunted but not eliminated. Before mepolizumab treatment, bronchoalveolar lavage eosinophils had more surface IL-3 and granulocyte-monocyte colony-stimulating factor receptors, CD69, CD44, and CD23 and decreased IL-5 and eotaxin receptors than blood eosinophils. This activation phenotype indicated by bronchoalveolar lavage eosinophil surface markers, as well as the release of eosinophil peroxidase by eosinophils in the bronchial mucosa, was maintained after mepolizumab. Mepolizumab reduced airway eosinophil numbers but had a limited effect on airway eosinophil activation markers, suggesting that these cells retain functionality. This observation may explain why IL-5 neutralization reduces but does not completely eradicate asthma exacerbations. Clinical trial registered with www.clinicaltrials.gov (NCT00802438).

Dates et versions

hal-04507235 , version 1 (16-03-2024)

Identifiants

Citer

Elizabeth A Kelly, Stéphane Esnault, Lin Ying Liu, Michael D Evans, Mats W Johansson, et al.. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.. American Journal of Respiratory and Critical Care Medicine, 2017, American Journal of Respiratory and Critical Care Medicine, 196, pp.1385-1395. ⟨10.1164/rccm.201611-2234OC⟩. ⟨hal-04507235⟩

Collections

UNIV-LILLE
14 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More